Rhumbline Advisers Arvinas, Inc. Transaction History

Rhumbline Advisers

$113 Billion
Q2 2025

A detailed history of Rhumbline Advisers transactions in Arvinas, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 102,077 shares of ARVN stock, worth $693,102. This represents 0.0% of its overall portfolio holdings.

Number of Shares

102,077

Previous 91,210 11.91%

Holding current value

$693,102

Previous $640,000 17.34%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	BUY	$6.07 - $9.62 $65,962 - $104,540	10,867 Added 11.91%	102,077 $751,000
Q1 2025 Apr 08, 2025	BUY	$7.02 - $20.5 $23,397 - $68,326	3,333 Added 3.79%	91,210 $692,000
Q4 2024 May 29, 2025	SELL	$17.83 - $28.04 $59,427 - $93,457	-3,333 Reduced 3.65%	87,877 $1.68 Million
Q4 2024 Jan 30, 2025	BUY	$17.83 - $28.04 $13,443 - $21,142	754 Added 0.87%	87,877 $1.68 Million
Q3 2024 Nov 12, 2024	SELL	$23.66 - $32.73 $73,487 - $101,659	-3,106 Reduced 3.44%	87,123 $2.15 Million
Q2 2024 Aug 01, 2024	BUY	$24.46 - $40.4 $465,327 - $768,569	19,024 Added 26.72%	90,229 $2.4 Million
Q1 2024 May 09, 2024	BUY	$36.38 - $52.31 $84,219 - $121,097	2,315 Added 3.36%	71,205 $2.94 Million
Q4 2023 Feb 08, 2024	SELL	$14.19 - $42.33 $1,560 - $4,656	-110 Reduced 0.16%	68,890 $2.84 Million
Q3 2023 Nov 09, 2023	BUY	$19.64 - $28.21 $5,459 - $7,842	278 Added 0.4%	69,000 $1.36 Million
Q2 2023 Aug 08, 2023	BUY	$21.73 - $31.43 $57,910 - $83,760	2,665 Added 4.03%	68,722 $1.71 Million
Q1 2023 May 11, 2023	BUY	$26.15 - $37.26 $40,898 - $58,274	1,564 Added 2.43%	66,057 $1.81 Million
Q4 2022 Feb 14, 2023	BUY	$32.47 - $57.24 $27,696 - $48,825	853 Added 1.34%	64,493 $2.21 Million
Q3 2022 Nov 10, 2022	BUY	$41.87 - $57.99 $212,573 - $294,415	5,077 Added 8.67%	63,640 $2.83 Million
Q2 2022 Aug 11, 2022	BUY	$36.01 - $74.24 $332,696 - $685,903	9,239 Added 18.73%	58,563 $2.47 Million
Q1 2022 May 12, 2022	BUY	$60.27 - $81.57 $89,139 - $120,642	1,479 Added 3.09%	49,324 $3.32 Million
Q4 2021 Feb 10, 2022	BUY	$65.85 - $96.21 $46,555 - $68,020	707 Added 1.5%	47,845 $3.93 Million
Q3 2021 Nov 12, 2021	BUY	$73.2 - $107.87 $123,488 - $181,976	1,687 Added 3.71%	47,138 $3.87 Million
Q2 2021 Aug 05, 2021	BUY	$60.45 - $84.26 $401,448 - $559,570	6,641 Added 17.11%	45,451 $3.5 Million
Q1 2021 May 06, 2021	SELL	$58.19 - $91.37 $22,228 - $34,903	-382 Reduced 0.97%	38,810 $2.57 Million
Q4 2020 Feb 10, 2021	BUY	$20.19 - $84.93 $42,701 - $179,626	2,115 Added 5.7%	39,192 $3.33 Million
Q3 2020 Nov 12, 2020	SELL	$22.99 - $36.34 $121,732 - $192,420	-5,295 Reduced 12.5%	37,077 $875,000
Q2 2020 Aug 13, 2020	BUY	$29.88 - $56.74 $444,345 - $843,780	14,871 Added 54.07%	42,372 $1.42 Million
Q1 2020 May 06, 2020	BUY	$33.0 - $54.5 $73,062 - $120,663	2,214 Added 8.76%	27,501 $1.11 Million
Q4 2019 Feb 05, 2020	BUY	$15.39 - $44.38 $99,973 - $288,292	6,496 Added 34.57%	25,287 $1.04 Million
Q3 2019 Oct 23, 2019	BUY	$21.55 - $27.61 $8,189 - $10,491	380 Added 2.06%	18,791 $405,000
Q2 2019 Aug 14, 2019	BUY	$15.96 - $23.8 $293,839 - $438,181	18,411 New	18,411 $405,000

Others Institutions Holding ARVN

# of Institutions

243

Shares Held

67.2M

Call Options Held

2.92M

Put Options Held

531K

View Full List

About ARVINAS, INC.

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $361M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

More about ARVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Arvinas, Inc. Transaction History